Axonics, a medical technology company specializing in bladder and bowel dysfunction treatments, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, at 4:30 p.m. PT on January 11. In advance, Axonics will release preliminary unaudited 2022 financial results and initial 2023 guidance before the market opens on the same day. The company ranks first on the Financial Times' 2022 fastest-growing companies in the Americas and fourth on Deloitte's Technology Fast 500.
Axonics (NASDAQ: AXNX) has received approval from Health Canada for its fourth-generation rechargeable sacral neuromodulation system, the Axonics R20 neurostimulator. This innovative device offers a functional life of at least 20 years and extends recharge intervals to every 6 to 10 months, a significant improvement from the previous model's monthly requirement. The R20 is now being sold in Canada, with FDA review ongoing for potential approval in the U.S., anticipated in Q1 2023. This advancement demonstrates Axonics' commitment to enhancing patient experiences and expanding market reach.
Axonics, Inc. (Nasdaq: AXNX), a medical technology company, will participate in the Piper Sandler Healthcare Conference on December 1, 2022, presenting at 11:00 a.m. Eastern Time. Investors can access a live webcast and replay on the Axonics investor relations website. The company specializes in treatments for bladder and bowel dysfunction, ranking No. 1 on the Financial Times' list of the 500 fastest-growing companies in the Americas in 2022, and No. 4 on Deloitte's Technology Fast 500. Axonics offers sacral neuromodulation systems and Bulkamid® for symptom relief.
Axonics, Inc. has been ranked No. 4 on the 2022 Deloitte Technology Fast 500, recognizing its remarkable growth in North America. The company reported a revenue increase from $707,000 in 2018 to $180.3 million in 2021, translating to a stunning growth rate of 25,401%. This marks Axonics' second consecutive year in the top 5. CEO Raymond W. Cohen attributed this success to the company's mission-driven culture and its innovative incontinence solutions aimed at improving quality of life for millions suffering from bladder and bowel dysfunction.
Axonics reported record quarterly revenue of $70 million, marking a 50% increase year-over-year. The company raised its fiscal year 2022 revenue guidance to $262 million, up 45% from the previous year. Sacral neuromodulation revenue reached $56.9 million, driven by the successful launch of the Axonics F15™ system. Gross margin improved to 72.8% from 66.5%. Though operating expenses rose to $67.6 million, the net loss narrowed to $16.3 million from $17.3 million in the prior year. Cash reserves stood at $350 million as of September 30, 2022.
Axonics (NASDAQ: AXNX), a medical technology firm, will announce its Q3 2022 financial results after market close on October 31. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested participants can register in advance via a provided link. The company specializes in products for bladder and bowel dysfunction and has recently achieved notable rankings in growth metrics.
Axonics, Inc. (NASDAQ: AXNX) announced the first Canadian implants of its Axonics F15™ sacral neuromodulation system, which offers a long-lived, fully recharge-free solution for bladder and bowel dysfunction. The University of Alberta performed the procedures on four patients, expecting battery longevity of 18 to 22 years. This follows previous FDA and Health Canada approvals. The Axonics F15 aims to enhance adoption of sacral neuromodulation therapy, significantly improving quality of life for millions suffering from incontinence in North America.
Axonics, Inc. (NASDAQ: AXNX), headquartered in location value="LU/us.ca.irvine"Irvine, California, has announced its participation in key investor conferences. Senior management will present at the Wells Fargo Healthcare Conference on September 8, 2022 at 10:25 a.m. ET, followed by the Morgan Stanley Healthcare Conference on September 12, 2022 at 11:05 a.m. ET. Interested investors can access the live and archived webcasts on the Axonics investor relations website.
Axonics, Inc. (NASDAQ: AXNX) has announced the granting of eight patents and the allowance of four patent applications related to its sacral neuromodulation technology over the past year. These patents cover innovations such as the Axonics external trial system and implantable neurostimulator. CEO Raymond W. Cohen emphasized the company’s commitment to addressing the needs of adults with incontinence. Axonics' product portfolio includes clinically proven therapies for overactive bladder and fecal incontinence, with established reimbursement coverage in the U.S. and Europe.
Axonics, Inc. (NASDAQ: AXNX) has successfully closed its public offering of 2,012,500 shares of common stock at $63.85 per share, with gross proceeds of approximately $128.5 million. The offering included the full exercise of the underwriter's option to purchase an additional 262,500 shares. BofA Securities acted as the sole book-running manager for this offering, which was conducted under an existing shelf registration statement filed with the SEC. Axonics specializes in innovative treatments for bladder and bowel dysfunction.